Copy for the designated Office (DO/US)

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF THE RECORDING OF A CHANGE

(PCT Rule 92bis.1 and Administrative Instructions, Section 422)

To:

WONG, King, L.
Arent Fox Kintner Plotkin & Kahn, PLLC
1050 Connecticut Avenue, N.W.
Suite 600
Washington, DC 20036-5339
ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year)
26 January 2001 (26.01.01)

Applicant's or agent's file reference
F108172-0000

International application No.
PCT/US00/06700

IMPORTANT NOTIFICATION

International filing date (day/month/year)
05 May 2000 (05.05.00)

1. The following indications appeared on record concerning:
[X] the applicant [X] the inventor [ ] the agent [ ] the common representative

Name and Address

State of Nationality | State of Residence

Telephone No.

Facsimile No.

Teleprinter No.

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:
[X] the person [ ] the name [ ] the address [ ] the nationality [ ] the residence

Name and Address
COLLINS, Peter, L.
12304 Village Square, Apt. 401
Rockville, MD 20852
United States of America

State of Nationality: US | State of Residence: US

Telephone No.

Facsimile No.

Teleprinter No.

3. Further observations, if necessary:
The applicant/inventor for US only has been added.

4. A copy of this notification has been sent to:
[X] the receiving Office
[ ] the International Searching Authority
[ ] the International Preliminary Examining Authority
[X] the designated Offices concerned
[ ] the elected Offices concerned
[ ] other:

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer
S. De Michiel

Telephone No.: (41-22) 338.83.38

003799029

Form PCT/IB/306 (March 1994)

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
US Department of Commerce
United States Patent and Trademark
Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 12 March 2001 (12.03.01)	
International application No. PCT/US00/06700	**Applicant's or agent's file reference** F108172-0000
International filing date (day/month/year) 05 May 2000 (05.05.00)	**Priority date** (day/month/year) 05 May 1999 (05.05.99)
Applicant SAMAL, Siba, K. et al	

1. The designated Office is hereby notified of its election made:

[X] in the demand filed with the International Preliminary Examining Authority on:

04 December 2000 (04.12.00)

[ ] in a notice effecting later election filed with the International Bureau on:

2. The election [X] was

[ ] was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO **34, chemin des Colombettes** **1211 Geneva 20, Switzerland**	Authorized officer C. Cupello
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

Form PCT/IB/331 (July 1992)

US0006700

IN THE UNITED STATES RECEIVING OFFICE

Hand Carry to PCT
Attn: IPEA/US

In re the application of: UNIVERSITY OF MARYLAND
PCT International Application Number: PCT/US00/06700
Filed: 05 May 2000
For: Production of Novel Newcastle Disease Virus Strains from cDNAs and Improved Live Attenuated Newcastle Disease Vaccines

DEMAND FOR INTERNATIONAL PRELIMINARY EXAMINATION

Commissioner for Patents
Box PCT
Washington, D.C. 20231

04 December 2000

Sir:

Enclosed is a PCT Demand for International Preliminary Examination. Applicants respectfully request that the above-identified International Application be the subject of international preliminary examination under Article 31 of the Patent Cooperation Treaty.

Respectfully submitted,
ARENT FOX KINTNER PLOTKIN & KAHN, PLLC

King L. Wong

King L. Wong
Appointed Agent

Agent's File Ref. No. 108172-00002
ARENT FOX KINTNER PLOTKIN & KAHN, PLLC
1050 Connecticut Avenue, N.W.
Suite 600
Washington, D.C. 20036-5339
KLW/arw

Enclosures

The demand must be filed directly with the competent International Preliminary Examining Authority or, if two or more Authorities are with the one chosen by the applicant. The full name or two-letter code of that Authority may be indicated by the applicant on the line

IPEA/ US

PCT

CHAPTER II

DEMAND

under Article 31 of the Patent Cooperation Treaty:
The undersigned requests that the international application specified below be the subject of international preliminary examination according to the Patent Cooperation Treaty and hereby elects all eligible States (except where otherwise indicated).

For International Preliminary Examining Authority use only

Identification of IPEA	Date of receipt of DEMAND

Box No. I IDENTIFICATION OF THE INTERNATIONAL APPLICATION

Applicant's or agent's file reference: 108172-00002

International application No.	International filing date *(day/month/year)*	(Earliest) Priority date *(day/month/year)*
PCT/US00/06700	05 May 2000 (05/05/00)	05 May 1999 (05/05/99)

Title of invention
Production of Novel Newcastle Disease Virus Strains from cDNAs and Improved Live Attenuated Newcastle Disease Vaccines

Box No. II APPLICANT(S)

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

UNIVERSITY OF MARYLAND
Office of Technology Liaison
4312 Knox Road
College Park, Maryland 20742
US

Telephone No.: 301/405-4209
Facsimile No.: 301/314-9871
Teleprinter No.:

State *(that is, country)* of nationality:	State *(that is, country)* of residence:
US	US

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

SAMAL, Siba K.
3508 Marlborough Way
College Park, Maryland 20740
US

State *(that is, country)* of nationality:	State *(that is, country)* of residence:
US	US

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

COLLINS, Peter L.
12304 Village Square
Apartment 401
Rockville, Maryland 20852
US

State *(that is, country)* of nationality:	State *(that is, country)* of residence:
US	US

☐ Further applicants are indicated on a continuation sheet.

International application No.
PCT/US00/06700

Box No. III AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The following person is ☒ agent ☐ common representative

and ☒ has been appointed earlier and represents the applicant(s) also for international preliminary examination.

☐ is hereby appointed and any earlier appointment of (an) agent(s) /common representative is hereby revoked.

☐ is hereby appointed, specifically for the procedure before the International Preliminary Examining Authority, in addition to the agent(s)/common representative appointed earlier.

Name and address: *(Family name followed by given name; for a legal entity, full official The address must include postal code and name of country.)*

WONG, King L.
ARENT FOX KINTNER PLOTKIN & KAHN, PLLC
1050 Connecticut Avenue, N.W.
Suite 600
Washington, D.C. 20036-5339
US

Telephone No.: 202/857-6000

Facsimile No.: 202/638-4810

Teleprinter No.:

☐ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

Box No. IV BASIS FOR INTERNATIONAL PRELIMINARY EXAMINATION

Statement concerning amendments:*

1. The applicant wishes the international preliminary examination **to start on the basis of:**

☒ the international application as originally filed.

the description ☐ as originally filed
☐ as amended under Article 34

the claims ☐ as originally filed
☐ as amended under Article 19 (together with any accompanying statement)
☐ as amended under Article 34

the drawings ☐ as originally filed
☐ as amended under Article 34

2. ☐ The applicant wishes any amendment to the claims under Article 19 to be considered as reversed.

3. ☐ The applicant wishes the start of the international preliminary examination **to be postponed** until the expiration of 20 months from the priority date unless the International Preliminary Examing Authority receives a copy of any amendments made under Article 19 or a notice from the applicant that he does not wish to make such amendments (Rule 69.1(d)). *(This check-box may be marked only where the time limit under Article 19 has not yet expired.)*

* Where no check-box is marked, international preliminary examination will start on the basis of the international application as originally filed or, where a copy of amendments to the claims under Article 19 and/or amendments of the international application under Article 34 are received by the International Preliminary Examining Authority before it has begun to draw up a written opinion or the international preliminary examination report, as so amended.

Language for the purposes of international preliminary examination: English

☒ which is the language in which the international application was filed.
☐ which is the language of a translation furnished for the purposes of international search.
☐ which is the language of publication of the international application.
☐ which is the language of the translation (to be) furnished for the purposes of international preliminary examination.

Box No. V ELECTION OF STATES

The applicant hereby **elects all eligible States** *(that is, all States which have been designated and which are bound by Chapter II of the PCT)*

excluding the following States which the applicant wishes **not to elect:**

Sheet No. 3

International application No.
PCT/US00/06700

Box No. VI CHECK LIST

The demand is accompanied by the following elements, in the language referred to in Box No. IV, for the purposes of international preliminary examination:			For International Preliminary Examining Authority use only: received	not received
1. translation of international application	:	sheets	☐	☐
2. amendments under Article 34	:	sheets	☐	☐
3. copy (or where required, translation) of amendments under Article 19	:	sheets	☐	☐
4. copy (or, where required, translation) of statement under Article 19	:	sheets	☐	☐
5. letter	:	sheets	☐	☐
6. other *(specify)* Cover Letter	:	1 sheets	☐	☐

The demand is also accompanied by the item(s) marked below:

1. ☒ fee calculation sheet
2. ☐ separate signed power of attorney
3. ☐ copy of general power of attorney; reference number, if any:
4. ☐ statement explaining lack of signature
5. ☐ nucleotide and or amino acid sequence listing in computer readable form
6. ☒ other *(specify)*: Request for Change Under PCT Rule

Box No. VII SIGNATURE OF APPLICANT, AGENT OR COMMON REPRESENTATIVE

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the demand).

King L. Wong
King L. WONG

For International Preliminary Examining Authority use only

1. Date of actual receipt of DEMAND:
2. Adjusted date of receipt of demand due to CORRECTIONS under Rule 60.1(b):
3. ☐ The date of receipt of the demand is AFTER the expiration of 19 months from the priority date and item 4 or 5, below, does not apply. ☐ The applicant has been informed accordingly.
4. ☐ The date of receipt of the demand is WITHIN the period of 19 months from the priority date as extended by virtue of Rule 80.5.
5. ☐ Although the date of receipt of the demand is after the expiration of 19 months from the priority date, the delay in arrival is EXCUSED pursuant to Rule 82.

For International Bureau use only

Demand received from IPEA on:

CHAPTER II

PCT

FEE CALCULATION SHEET

Annex to the Demand for international preliminary examination

International application No.	**PCT/US00/06700**
Applicant's or agent's file reference	**108172-00002**

For International Preliminary Examining Authority use only

Date stamp of the IPEA

Applicant
UNIVERSITY OF MARYLAND, et al.

Calculation of prescribed fees

1. Preliminary examination fee	490.00	P
2. Handling fee *(Applicants from certain States are entitled to a reduction of 75% of the handling fee. Where the applicant is (or all applicants are) so entitled, the amount to be entered at H is 25% of the handling fee.)*	153.00	H
3. Total of prescribed fees Add the amounts entered at P and H and enter total in the TOTAL box	643.00 TOTAL	

Mode of Payment

- ☐ authorization to charge deposit account with the IPEA (see below)
- ☒ cheque
- ☐ postal money order
- ☐ bank draft
- ☐ cash
- ☐ revenue stamps
- ☐ coupons
- ☐ other *(specify)*:

Deposit Account Authorization *(this mode of payment may not be available at all IPEAs)*

The IPEA/ **US** ☐ is hereby authorized to charge the total fees indicated above to my deposit account.

☒ *(this check-box may be marked only if the conditions for deposit accounts of the IPEA so permit)* is hereby authorized to charge any deficiency or credit any overpayment in the total fees indicated above to my deposit account.

01-2300	**04 December 2000 (04/12/00)**	King L. Wong
Deposit Account Number	Date *(day/month/year)*	Signature

IN THE INTERNATIONAL BUREAU OF WIPO

In re the application of: University of Maryland, et al.

International Application Number: PCT/US00/06700

Filed: 05 May 2000

For: Production of Novel Newcastle Disease Virus Strains from cDNAs and Improved Live Attenuated Newcastle Disease Vaccines

REQUEST FOR CHANGE UNDER PCT RULE 92 bis

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

04 December 2000

Dear Sir:

Applicants respectfully request that the title of International Application Number PCT/US00/06700 be amended to read as follows:

Production of Novel Newcastle Disease Virus Strains from cDNAs and Improved Live Attenuated Newcastle Disease Vaccines

Applicants request that the International Bureau acknowledge receipt of this request for change under PCT Rule 92bis by issuance of PCT form IB/306.

Respectfully submitted,

ARENT FOX KINTNER PLOTKIN & KAHN

King L. Wong

King L. Wong
Appointed Agent

Agents File Reference No. 108172-00002
ARENT FOX KINTNER PLOTKIN & KAHN, PLLC
1050 Connecticut Avenue, N.W.
Suite 600
Washington, D.C. 20036-5339
United States of America

KLW/arw

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

To: KING L. WONG
ARENT FOX KINTNER PLOTKIN & KAHN, PLLC
1050 CONNECTICUT AVENUE, N.W.
SUITE 600
WASHINGTON, DC 20036 5339

PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION

(PCT Rule 44.1)

	Date of Mailing *(day/month/year)* 30 AUG 2000
Applicant's or agent's file reference F108172-0000	FOR FURTHER ACTION See paragraphs 1 and 4 below
International application No. PCT/US00/06700	International filing date *(day/month/year)* 05 MAY 2000
Applicant UNIVERSITY OF MARYLAND	

1. [X] The applicant is hereby notified that the international search report has been established and is transmitted herewith.

Filing of amendments and statement under Article 19:
The applicant is entitled, if he so wishes, to amend the claims of the international application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the international search report; however, for more details, see the notes on the accompanying sheet.

Where? Directly to the International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland
Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. [ ] The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. [ ] **With regard to the protest** against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

[ ] the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

[ ] no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after **18 months** from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in rules 90 *bis* 1 and 90 *bis* 3, respectively, before the completion of the technical preparations for international publication.

Within **19 months** from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within **20 months** from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer LAURIE SCHEINER
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

Form PCT/ISA/220 (July 1998)★

(See notes on accompanying sheet)

PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To: KING L. WONG
ARENT FOX KINTNER PLOTKIN & KAHN, PLLC
1050 CONNECTICUT AVENUE, N.W.
SUITE 600
WASHINGTON, DC 20036 5339

PCT

NOTIFICATION OF TRANSMITTAL OF INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Rule 71.1)

Date of Mailing *(day/month/year)*	21 MAR 2001
Applicant's or agent's file reference: 108172-00002	IMPORTANT NOTIFICATION

International application No.	International filing date *(day/month/year)*	Priority Date *(day/month/year)*
PCT/US00/06700	05 MAY 2000	05 MAY 1999

Applicant
UNIVERSITY OF MARYLAND

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international

2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.

3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/US	Authorized officer
Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	LAURIE SCHEINER for Laurie Budgers
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

Form PCT/IPEA/416 (July 1992)★

ENT COOPERATION TREATY

PCT

From the INTERNATIONAL BUREAU

To:

WONG, King, L.
Ar nt Fox Kintner Plotkin & Kahn,
PLLC
1050 Connecticut Avenue, N.W.
Suite 600
Washington, D.C. 20036-5339
ETATS-UNIS D'AMERIQUE

NOTIFICATION CONCERNING SUBMISSION OR TRANSMITTAL OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

Date of mailing (day/month/year) 13 September 2000 (13.09.00)	
Applicant's or agent's file reference F108172-00002	**IMPORTANT NOTIFICATION**
International application No. PCT/US00/06700	International filing date (day/month/year) 05 May 2000 (05.05.00)
International publication date (day/month/year) Not yet published	Priority date (day/month/year) 05 May 1999 (05.05.99)
Applicant UNIVERSITY OF MARYLAND et al	

1. The applicant is hereby notified of the date of receipt (except where the letters "NR" appear in the right-hand column) by the International Bureau of the priority document(s) relating to the earlier application(s) indicated below. Unless otherwise indicated by an asterisk appearing next to a date of receipt, or by the letters "NR", in the right-hand column, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).

2. This updates and replaces any previously issued notification concerning submission or transmittal of priority documents.

3. An **asterisk(*)** appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b). In such a case, **the attention of the applicant is directed** to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

4. The **letters "NR"** appearing in the right-hand column denote a priority document which was not received by the International Bureau or which the applicant did not request the receiving Office to prepare and transmit to the International Bureau, as provided by Rule 17.1(a) or (b), respectively. In such a case, **the attention of the applicant is directed** to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

Priority date	Priority application No.	Country or regional Office or PCT receiving Office	Date of receipt of priority document
05 May 1999 (05.05.99)	60/132,597	US	05 Augu 2000 (05.08.00)
16 Dece 1999 (16.12.99)	60/171,072	US	05 Augu 2000 (05.08.00)

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No. (41-22) 740.14.35

Authorized officer

R. Raissi

Telephone No. (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 108172-00002	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/US00/06700	International filing date *(day/month/year)* 05 MAY 2000	Priority date *(day/month/year)* 05 MAY 1999
International Patent Classification (IPC) or national classification and IPC Please See Supplemental Sheet.		
Applicant UNIVERSITY OF MARYLAND		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 4 sheets.

   ☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consist of a total of 0 sheets.

3. This report contains indications relating to the following items:

   I ☒ Basis of the report

   II ☐ Priority

   III ☐ Non-establishment of report with regard to novelty, inventive step or industrial applicability

   IV ☐ Lack of unity of invention

   V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

   VI ☐ Certain documents cited

   VII ☐ Certain defects in the international application

   VIII ☐ Certain observations on the international application

Date of submission of the demand	Date of completion of this report
04 DECEMBER 2000	10 MARCH 2001
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer Jayer Bridgers for LAURIE SCHEINER
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

Form PCT/IPEA/409 (cover sheet) (July 1998)★

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US00/06700

I. Basis of the report

1. With regard to the **elements** of the international application:*

[X] the international application as originally filed

[X] the description:
pages 1-25 , as originally filed
pages NONE , filed with the demand
pages NONE , filed with the letter of _____

[X] the claims:
pages 26-29 , as originally filed
pages NONE , as amended (together with any statement) under Article 19
pages NONE , filed with the demand
pages NONE , filed with the letter of _____

[X] the drawings:
pages 1-17 , as originally filed
pages NONE , filed with the demand
pages NONE , filed with the letter of _____

[X] the sequence listing part of the description:
pages NONE , as originally filed
pages NONE , filed with the demand
pages NONE , filed with the letter of _____

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.
These elements were available or furnished to this Authority in the following language _____ which is:

[ ] the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).

[ ] the language of publication of the international application (under Rule 48.3(b)).

[ ] the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

[ ] contained in the international application in printed form.

[ ] filed together with the international application in computer readable form.

[ ] furnished subsequently to this Authority in written form.

[ ] furnished subsequently to this Authority in computer readable form.

[ ] The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

[ ] The statement that the information recorded in computer readable form is identical to the writen sequence listing has been furnished.

4. [X] The amendments have resulted in the cancellation of:

[X] the description, pages NONE

[X] the claims, Nos. NONE

[X] the drawings, sheets/~~fig~~ NONE

5. [ ] This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

** Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).*

***Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.*

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US00/06700

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. statement

Novelty (N)	Claims	1-27	YES
	Claims	NONE	NO
Inventive Step (IS)	Claims	1-27	YES
	Claims	NONE	NO
Industrial Applicability (IA)	Claims	1-27	YES
	Claims	NONE	NO

2. citations and explanations (Rule 70.7)

Claims 1-27 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest the Newcastle disease virus wild type strain Beaudette C amino acid variations. Moreover, the art fails to teach the nucleic acids which encode said variations.

NEW CITATIONS

NONE

Supplemental Box
(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

CLASSIFICATION:

The International Patent Classification (IPC) and/or the National classification are as listed below:

IPC(7): A61K 39/12, 39/17, 45/00; C12N 7/00, 7/04, 1/20 and US Cl.: 424/186.1, 204.1, 214.1, 281.1, 816; 435/235.1, 236, 252.3

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference F108172-0000	FOR FURTHER ACTION	see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.
International application No. PCT/US00/06700	International filing date *(day/month/year)* 05 MAY 2000	(Earliest) Priority Date *(day/month/year)* 05 MAY 1999
Applicant UNIVERSITY OF MARYLAND		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 3 sheets.

[X] It is also accompanied by a copy of each prior art document cited in this report.

1. **Basis of the report**

   a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

   [ ] the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

   b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing:

   [ ] contained in the international application in written form.

   [ ] filed together with the international application in computer readable form.

   [ ] furnished subsequently to this Authority in written form.

   [ ] furnished subsequently to this Authority in computer readable form.

   [ ] the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

   [ ] the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

2. [ ] **Certain claims were found unsearchable** (See Box I).

3. [ ] **Unity of invention is lacking** (See Box II).

4. With regard to the **title**,

   [X] the text is approved as submitted by the applicant.

   [ ] the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

   [X] the text is approved as submitted by the applicant.

   [ ] the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No. _____

   [ ] as suggested by the applicant.

   [ ] because the applicant failed to suggest a figure.

   [ ] because this figure better characterizes the invention.

   [X] None of the figures.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/05700

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :A61K 39/12, 39/17, 45/00; C12N 7/00, 7/04, 1/20

US CL :424/186.1, 204.1, 214.1, 281.1, 816; 435/235.1, 236, 252.3

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/186.1, 204.1, 214.1, 281.1, 816; 435/235.1, 236, 252.3

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST 2.0, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	YUSOFF, K. et al. Location of Neutralizing epitopes on the Fusion Protein of Newcastle Disease Virus Strain Beaudette C J. Gen. Virol. 1989, Vol. 70, pages 3105-3109, see entire document.	1-27
Y	KRISHNAMURTHY, S. et al. Nucleotide Sequences of the Trailer, Nucleocapsid Protein Gene and Intergenic Regions of Newcastle Disease Virus Strain Beaudette C and Completion of the Entire Genome Sequence. Journal of General Virology. 1998, Vol. 79, pages 2419-2424, see entire document.	1-27

[X] Further documents are listed in the continuation of Box C. [ ] See patent family annex.

*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

17 AUGUST 2000

Date of mailing of the international search report

30 AUG 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

LAURIE SCHEINER

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet) (July 1998)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/06700

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SCHAPER, U. M. et al. Nucleotide Sequence of the Envelope Protein Genes of a Highly Virulent, Neurotropic Strain of Newcastle Disease Virus. Virology. 1988, Vol. 165, pages 291-295, see entire document.	1-27
Y	YUSOFF, K. et al. Nucleotide Sequence Analysis of the L Gene of Newcastle Disease Virus: Homologies with Sendai and Vesicular Stomatitis Viruses. Nucleic Acids Research 1987, Vol. 15, No. 10, pages 3961-3976, see entire document.	1-27
Y	DASKALAKIS, S. et al. Nucleotide Sequence of the Phosphoprotein (P) Gene of Newcastle Disease Virus (Strain Beaudette C). Nucleic Acids Research. 1992, Vol. 20, No. 3, page 616, see entire document.	1-27

NOTES TO FORM PCT/ISA/220 (continued)

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under Article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

The statement should be brief, it should not exceed 500 words if in English or if translated into English.

It should not be confounded with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It should not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

In what language ?

The amendments must be made in the language in which the international application is published. The letter and any statement accompanying the amendments must be in the same language as the international application if that language is English or French; otherwise, it must be in English or French, at the choice of the applicant.

Consequence if a demand for international preliminary examination has already been filed ?

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase ?

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
A61K 39/12, 39/17, 45/00, C12N 7/00, 7/04, 1/20

A1

(11) International Publication Number: WO 00/67786

(43) International Publication Date: 16 November 2000 (16.11.00)

(21) International Application Number: PCT/US00/06700

(22) International Filing Date: 5 May 2000 (05.05.00)

(30) Priority Data:
60/132,597 5 May 1999 (05.05.99) US
60/171,072 16 December 1999 (16.12.99) US

(71) Applicant *(for all designated States except US)*: UNIVERSITY OF MARYLAND [US/US]; Office of Technology Liaison, 4312 Knox Road, College Park, MA 20742 (US).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: SAMAL, Siba, K. [IN/US]; 3508 Marlborough Way, College Park, MD 20740 (US).

(74) Agents: WONG, King, L. et al.; Arent Fox Kintner Plotkin & Kahn, PLLC, 1050 Connecticut Avenue, N.W., Suite 600, Washington, DC 20036–5339 (US).

(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: PRODUCTION OF NOVEL NEWCASTLE DISEASE VIRUS STRAINS FROM cDNAS AND IMPROVED LIVE ATTENUATED NEWCASTLE DISEASE VACCINES

(57) Abstract

The present invention concerns cDNAs for making attenuated, infectious Newcastle disease virus (NDV). Another aspect of the invention relates to methods of making the cDNAs. Another aspect of the invention is a vector containing the cDNA optionally linked to an operable promoter. Within the scope of the invention are vaccines comprising the attenuated, infectious NDV. Also disclosed are methods of making the vaccines and methods of using the vaccines to prevent or treat Newcastle disease in an avian host. The present invention also concerns the nucleotide sequences of the entire genome of NDV, the leading region, the trailing region, and the NP region, as well as proteins encoded by these nucleotide sequences.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

Production of Novel New Castledisease Virus Strains from cDNAs and Improv d Live Attenuated Newcastle Disease Vaccines

The present invention relates to Newcastle disease virus (NDV). In particular, the invention concerns the production of novel NDV strains from cDNAs and the production of improved Newcastle disease vaccines.

Background of the Invention

Newcastle disease virus (NDV) causes a highly contagious and fatal disease affecting all species of birds. Newcastle disease can vary from mild to highly virulent depending upon the virus strain and the host species (1). The virus is a member of the family Paramyxoviridae (2) and contains a single-stranded negative-sense RNA genome.

The genome of NDV is a single strand negative-sense RNA, which has been founded to consist of 15,186 nucleotides (3). The genomic RNA contains six structural genes, which encode at least seven proteins (4,5). Three proteins constitute the nucleocapsid; specifically the nucleoprotein (NP), the phosphoprotein (P), and the large polymerase protein (L). Two proteins form the external envelope spikes, namely the F and HN proteins. The matrix protein (M) forms the inner layer of the virion. The genomic RNA is tightly bound by the NP protein and with the P and L proteins form the functional nucleocapsid within which resides the viral transcriptive and replicative activities. The HN glycoprotein is responsible for attachment of virus to host cell receptors and the F glycoprotein mediates fusion of the viral envelope with the host cell plasma membrane thereby enabling penetration of viral genome into cytoplasm (6). The HN and F proteins are the main targets for the immune response (7, 8). In common with several other Paramyxoviruses, NDV produces a seventh protein (V) of unknown function by editing of the P gene (5, 9).

NDV follows the general scheme of transcription and replication of other nonsegmented negative-strand RNA viruses. The polymerase enters the genome at a promoter in the 3'extragenic leader region and proceeds along the entire length by a sequential stop-start mechanism during which the polymerase remains template bound and is guided by short consensus gene-start (GS) and gene-end (GE) signals. This generates a free leader RNA and six nonoverlapping subgenomic mRNAs. The

abundance of the various mRNAs decreases with increasing gene distance from the promoter. The genes are separated by short intergenic regions (1-47 nucleotides) which are not copied into the individual mRNAs. The 3' terminus (leader) and the 5' terminus (trailer) of the genomic RNA contain the cis-acting sequences important for replication, transcription, and packaging of viral RNA (10). RNA replication occurs when the polymerase somehow switches to a readthrough mode in which the transcription signals are ignored. This produces a complete encapsulated positive-sense replicative intermediate which serves as the template for progeny genomes. A schematic of the genetic map of NDV genomic RNA is shown in Fig. 1.

Vaccination has been widely used to control Newcastle disease. The most commonly used method of vaccination has been the exposure of chickens to low virulence strains of NDV. Advantages of live Newcastle disease vaccines are that they can be mass-applied by natural routes of infection and that protection occurs very soon after application resulting in local as well as systemic immunity.

The main disadvantage of live Newcastle disease vaccines is that they can cause disease and can lead to mortality. Thus, development of a completely apathogenic NDV vaccine would be beneficial to the poultry industry. Before the present invention was made, there was no method available to directly manipulate the genome of NDV to achieve a desired level of attenuation.

A few years ago, two alternative approaches were developed for nonsegmented negative-stranded RNA viruses. In one approach, synthetic "minigenomes" consisting of genomic terminal sequences surrounding a reporter gene were transcribed from cDNA in vitro and transfected into cells infected with wild type helper virus. The second approach involved co-expression of minigenomes and necessary nucleocapsid proteins from transfected plasmids using the transient vaccinia virus/T7 RNA polymerase expression system. These approaches have made it possible to begin the characterization of cis-and trans-acting factors required for transcription and replication of several nonsegmented negative-stranded RNA viruses. Recently, the second approach was used to recover complete infectious recombinant virus from full-length cDNA for several nonsegmented negative-strand RNA viruses, namely, rabies

virus, vesicular stomatitis virus, measles virus, Sendai virus, human respiratory syncytial virus, rinderpest virus and parainfluenza 3 virus.

Another major disadvantage of currently available NDV vaccines is that the avirulent vaccine viruses can change to virulent viruses by reversion of up to a few, e.g. one or two, nucleotides at the cleavage site. For instance, currently available NDV vaccines that are of low virulence strains differ from virulent strains by only one or two nucleotides in the F_0 protein cleavage site, which is fifteen nucleotides long. Therefore, reversion of these few nucleotides can change the phenotype of the NDV from low virulence to highly virulence. Recently, it was shown that an outbreak of Newcastle disease in Australia was caused by a mutation in the cleavage site on F_0 protein of pre-existing avirulent field strains circulatory in eastern Australia (XI International Congress of Virology Abstracts, VET.06, pp. 102).

Summary of the Invention

A part of the present invention is based on the new idea that, since the genomes typically contain many changes, the ability to directly engineer mutations into cDNA would make it possible to generate defined attenuated strains where cDNA would serve as a stable vaccine "seed."

As discussed above, one of limitations of currently used live attenuated vaccines is their reversion to virulence. One of the aims of the present invention is to overcome this limitation of reversion to virulence by designing attenuating mutation(s) in the genome, which is less likely to revert back to virulence.

Sequence analysis of several avirulent strains shows that attenuation in NDV occurs by three different mechanisms: (1) avirulent strains have few basic amino acid residues, x-Arg/Lys-x-x-Arg, at the F_0 protein cleavage site, whereas virulent strains have multibasic residues, Arg-Arg-x-Arg/Lys-Arg, at the F_0 protein cleavage site, (2) in some avirulent strains the open reading frame of the HN glycoprotein extends beyond the C terminus of more virulent strains and this terminal extension was assumed to be responsible for the origin of the HN precursor (HN_0) found in avirulent strains, and (3) in some avirulent strains a leucine residue is present at the N terminus of the F_1 cleavage fragment in place of a phenylalanine residue at this position in virulent strains. Of the three mechanisms, the number of basic residue at the F_0

protein cleavage site is the major determinant of NDV virulence. It is thought that those strains with few basic residues at the cleavage site are cleaved only by the proteases of the Clara cells in the bronchial epithelium whereas those strains with multibasic residues at the cleavage site are cleaved by the protease furin present in cells throughout the animal.

In one embodiment of the present invention, the genetic codes of the amino acids in the cleavage site of NDV are changed to make recombinant NDV strains containing the same amino acids as other avirulent strains but will require reversion of several, e.g. 3, 4, 5 or 6, nucleotides before the avirulent recombinant NDV strains are reverted to virulent strains. In another embodiment of the present invention, NDV vaccines are produced that contain the presence of leucine in the +1 position as a mechanism of attenuation. In still another embodiment of the present invention, NDV vaccines are produced that contain cleavable HN protein as a mechanism of attenuation. Within the scope of the present invention are NDV vaccines that work with two or three of these three attenuation mechanisms: (1) having the same amino acid sequence as other avirulent strains that require reversion of several, e.g. 3, 4, 5 or 6, nucleotides before reversion from avirulence to virulence occurs, (2) having leucine in the +1 position, and (3) having a cleavable HN protein. With the present invention's methods of direct manipulations of the NDV genome, production of these NDV vaccines of avirulent strains is possible for the first time.

With the methods of the present invention, the following products are developed:

(i) genetically engineered NDV vaccines that are more stable than currently available NDV vaccines;

(ii) genetically engineered NDV vaccines that are completely apathogenic;

(iii) multivalent genetically engineered NDV vaccines carrying immunogens for influenza virus, infectious bursal disease virus, rotavirus, infectious bronchitis virus, infectious laryngotrachetis virus, chicken anemia virus, Marek's disease virus, avian Leukosis virus and avian adenovirus; and

(iv) genetically engineered NDV stains that carry avian cytokine genes.

The present invention includes a method to produce infectious NDV from cloned cDNA. This method can be used to directly manipulate the genome of NDV. The method can also be used to engineer attenuated NDV vaccine strains by combining two or all of the three mechanisms of attenuation. Furthermore, the present inventor has designed nucleotide sequences at the cleavage site, which are less likely to revert back to virulence.

The present inventor recovered infectious NDV from cloned cDNA using a reverse genetics approach. This approach involves co-expression of full-length NDV genome and nucleocapsid proteins (NP, P and L) from transfected plasmids using the vaccinia virus/T7 RNA polymerase expression system. Within the scope of the present invention is a method to recover NDV with amino acid changes at the cleavage site. The codon of the changed amino acid is different from that of the original amino acid by at least two nucleotides. Such a difference in at least two nucleotides stabilizes the viral genome against reversion from a nonbasic amino acid residue to a basic amino acid residue. For instance, NDV with some or all of following changes at the cleavage site can be produced:

1. NDV in which the arginine residue (AGA) at the -2 position in the cleavage site has been changed to a serine residue (TCC).
2. NDV in which the arginine residue (AGG) at the -5 position in the cleavage site has been changed to a serine residue (TCC).
3. NDV in which the arginine residues at the -2 and -5 positions have been changed to serine residues (TCC).
4. NDV which contains serine (TCC) at the -2 and -5 position and leucine (CTC) at the +1 position.

The above changes are done not only in full-length cDNA clones of NDV Strain Beaudette C, but also in full-length cDNA clones of NDV Strain Ulster which has a cleavable HN protein. The genetically engineered NDV strains of the present invention are completely apathogenic and will not revert back to virulence phenotypes. These new NDV vaccine strains are better than the currently available NDV vaccines.

In addition to the development of live attenuated vaccines against Newcastle disease, this invention can lead to the development of vaccines against other poultry diseases. For example, genetically engineered NDV carrying VP2 protein of infectious bursal disease virus can be used as a bivalent vaccine in chickens.

Brief Description of Drawings

Fig. 1 is a schematic of the genetic map of NDV genomic RNA.

Fig. 2 is the complete map of the genome of NDV strain Beaudette C, wherein the nucleotide sequence of the NP region is available from the GenBank database with the accession number AF064091.

Fig. 3 shows the nucleotide sequences of the leader and trailer regions of NDV strain B1 in comparisons with corresponding sequences from NDV strain Beaudette C and NDV strain D26.

Fig. 4 shows the structure of a NDV RNA analog.

Fig. 5A demonstrates NDV minigenome transcription by CAT activity.

Fig. 5B demonstrates NDV minigenome replication by Northern hybridization.

Fig. 6 shows a cDNA-encoded NDV-CAT(-) minigenome.

Fig. 7 shows the transcription of NDV-CAT(-) minigenome in response to NDV N, P, and L proteins.

Fig. 8. Construction of NDV Strain Beaudette C antigenomic cDNA.

Fig. 9. Schematic procedure for the rescue of infectious NDV from full-length cDNA.

Fig. 10. Photomicrographs of immunological plaques of a laboratory NDV strain Beaudette C (A) and recombinant NDV strain Beaudette C (B).

Fig. 11. Identification of sequence markers in recombinant NDV strain Beaudette C by RT-PCR and restriction enzyme digestion.

Fig. 12. Recombinant NDVs showing location of cleavage site mutations.

Fig. 13. Construction of a recombinant NDV cDNA that contains an extra gene, chloramphenical acetyltransferase (CAT).

Fig. 14. Detection of CAT expression after one passage.

Fig. 15. Identification of sequence markers in recombinant NDV strain LaSota by RT-PCR and restriction enzyme digestion.

Fig. 16. Single-step growth curve of parental and recombinant NDV.

Fig. 17. Multi-step growth curve of parental and recombinant NDV.

Detailed Description of the Invention

The present invention have at least the following accomplishments: (1) the complete sequence of the genomic RNA of NDV strain Beaudette C was determined; (2) the leader and trailer sequences of the low virulence NDV strain B1 were determined.; (3) cDNAs for all six NDV genes were placed into T7-based expression vectors; (4) subgenomic cDNAs spanning the entire NDV genome were cloned and sequenced; (5) minigenome systems for NDV were developed; (6) information from minigenome systems was developed for rescuing infectious NDV from full-length cDNA; and (7) panels of monoclonal antibodies to NDV proteins were produced.

A. Completion of the entire genome sequence of NDV

Nucleotide sequences of several genes for different NDV strains were available in the prior art, but the complete genomic sequence was not established. In this respect, the Beaudette C strain of NDV has been the most well-characterized, with some of the nucleotide sequences already available:

(1) the complete nucleotide sequence of five genes, namely, P (Daskalakis et al, *Nucleic Acids Res.*, vol. 20, p. 616, 1992), M (Chambers et al, *Nucleic Acids Res.*, vol. 14, pp. 9051-9061, 1986), F (Chambers et al, *J. Gen. Virology*, vol. 67, pp. 2685-2694, 1986), HN (Millar et al, *J. Gen. Virology*, vol. 67, pp. 1917-1927, 1986), and L (Yusoff et al, *Nucleic Acids Res.*, vol. 15, pp. 3961-3976, 1987);

(2) a partial sequence, i.e. the first 192 nucleotides, of the NP gene (Kurilla et al, *Virology*, vol. 145, pp. 203-212, 1985);

(3) the sequences of the intergenic regions in the F-HN junction (Chambers et al, *J. Gen. Virology*, vol. 67, pp. 2685-2694, 1986) and HN-L junction (Chambers et al, *J. Gen. Virology*, vol. 67, pp. 475-486, 1986);

(4) the sequence of the leader region (Kurilla et al, *Virology*, vol. 145, pp. 203-212, 1985); and

(5) a partial sequence, i.e. the first 49 nucleotides, of the trailer sequence (Yusoff et al, *Nucleic Acids Res.*, vol. 15, pp. 3961-3976, 1987).

Previous to the present invention, the 5' trailer sequence of NDV was never determined. For the first time, the present inventor determined the 5' trailer sequence of NDV, as well as the nucleotide sequences for the NP gene and the NP-P, P-M and M-F intergenic regions, of the Beaudette C strain to complete the entire nucleotide sequence of the Beaudette C strain of NDV (Fig. 2, in genome RNA-sense). In Fig. 2, the last nucleotide of the gene end, the first nucleotide of the gene start and the first and last nucleotides of the leader and trailer are numbered. The sequences of the leader were derived from Kurilla et al (*Virology*, vol. 145, pp. 203-212, 1985); the intergenic region in the F-HN junction from Chambers et al (*J. Gen. Virology*, vol. 67, pp. 2685-2694, 1986) and the intergenic region in the HN-L junction from Chambers et al (*J. Gen. Virology*, vol. 67, pp. 475-486, 1986). The gene end and gene start sequences of NDV were derived from the published sources of the respective genes. The present invention includes the nucleotide sequences of the complete NP gene, the entire trailer region and the intergenic regions in the NP-P, P-M and M-F junctions.

NDV strain Beaudette C was received from the National Veterinary Services Laboratory at Ames, Iowa, U.S.A. and was propagated in the allantoic cavity of embryonated chicken eggs. The virus was purified as described previously (Kingsbury, *J. Mol. Biol.*, vol. 18, pp. 195-203, 1966). The virion RNA was extracted using proteinase K and TRIzol reagent (Life Technologies). The NP gene, intergenic regions and 5' trailer region were obtained by RT-PCR of the virion RNA. The cDNAs were synthesized using Superscript II reverse transcriptase (Life Technologies). The cDNA corresponding to the NP gene was synthesized using a positive-sense primer, 5' GAAGGTGTGAATCTCGAGTGCG, complementary to the established sequence at the start of the NP gene. This primer and a negative-sense primer corresponding to the 3' end of the P gene, 5' GCTCGTCGATCTCCGCATCTGT, were used in PCR with high fidelity *Pfu* DNA polymerase (Stratagene). The PCR product was cloned and sequenced by the dideoxynucleotide chain termination method. For obtaining cDNAs corresponding

to the intergenic regions, the positive-sense oligonucleotide primer was derived from a sequence upstream of the respective gene junction. Likewise, the negative-sense primer was derived from a sequence downstream of that gene junction. The PCR product was cloned and sequenced by the dideoxynucleotide chain termination method.

The 5' trailer region was cloned using the 5' RACE method (Dorit, in *Current Protocols in Molecular Biology*, vol. 2, pp. 15.6.1-15.6.10, 1995). Briefly, a positive-sense primer, 5' CACTAAGGACATACTTGAAGC, complemenatry to the downstream end of the L gene was extended with reverse transcriptase and the resulting cDNAs were tailed with dCTP, and separately with dGTP, using terminal deoxynucleotidy transferase. The cDNAs were then amplified by PCR by using the L gene-specific primer described above and either oligo(dG) primer for reactions tailed with dC, or oligo(dC) primer for reactions tailed with dG. The PCR products were then cloned and sequenced by the dideoxynucleotide chain termination method. Tailing reactions with C and G residues assured unambiguous determination of the 5' terminal nucleotide. To sequence the 3' leader region, virion RNA was ligated to a synthetic RNA, and cDNA was made using RT-PCR. The PCR product was cloned and sequenced by the dideoxynucleotide chain termination method.

The complete nucleotide sequence of the NP gene of the NDV strain Beaudette C is 1747 nucleotides long, including non-coding regions of 66 nt at the 3' end and 211 nt at the 5' end of the gene (the nucleotide sequence of the NP region is available from the GenBank database with the accession number AF064091). The major open reading frame of 1467 nt, extending from positive 122 to 1588 of the genomic RNA sequence, contained a coding region of 489 amino acid residues. The NP protein of Beaudette C strain showed 96% amino acid sequence identity with the NP proteins of two lentogenic NDV strains D26 and U2C. The 5' non-coding region of the NP gene of Beaudette C strain showed 31% and 29% sequence variation with the corresponding regions of strains D26 and U2C, respectively. Each of the intergenic regions in the NP-P, P-M and M-F junctions has only one nucleotide. The trailer sequence is 113 nt long in strain Beaudette C (Fig. 2).

Within the scope of the present invention are the nucleotide sequences of the leader and trailer regions of lentogenic NDV strain B1 (Fig. 3). Fig. 4a compares the nucleotide sequences of the leader regions of NDV strain B1 and NDV strain Beaudette C, and the previously published sequence of the leader region of NDV strain D26, in which identical nucleotides are indicated by asterisks. Nucleotides in the leader sequence of strain D26 that are different from those of strain B1 are underlined. Fig. 3b compares the trailer sequences from NDV strain B1 and strain Beaudette C, in which identical nucleotides are indicated by asterisks. The trailer region of strain B1 is 114 nt long, 1 nt longer than the trailer sequence of strain Beaudette C (Fig. 3b). The two sequences show a high level of identity, with only 7 nt differences throughout. The 5' terminal 22 nt are identical in the two sequences.

B. Cloning of NDV Genes into T7-based Plasmid Vectors

cDNAs of all six genes of NDV strain Beaudette C were placed into T7-based plasmid vectors. NDV genes were synthesized by RT-PCR and forced cloned into plasmid pTM-1. RT reactions were carried out using gene specific primers and superscript II RT (Life Technologies). High fidelity *Pfu* DNA polymerase (Stratagene) was used in PCR. The L gene was first synthesized in two different RT-PCR fragments. Then the two fragments were joined using a unique *Afl II* restriction site at positions 3026 in the L gene sequence. All genes were partially sequenced and correct expression was confirmed using rabbit reticulocyte lysate system (Promega).

Also, the N, P and L genes were found to be functional using a plasmid based NDV minigenome system.

C. Identification of cis-acting sequences required for transcription and replication of NDV RNA.

Another aspect of the present invention is the identification of the cis-acting signals required for NDV RNA transcription, replication, and packaging using an RNA based system. Briefly, a cDNA was constructed to encode a 978-nucleotide, internally deleted version of NDV genomic RNA, NDV(-), in which the viral genes were replaced with the bacterial chloramphenicol acetyl transferase (CAT) reporter gene (Fig. 4). The CAT gene was flanked in turn by sequences representing (i) noncoding sequences of the first and last genes in the NDV genome, (ii) NDV gene-

start and, gene-end sequences, (iii) 3' leader and 5' trailer sequences of NDV genomic RNA.

C. Rescue of NDV Minigenome

NDV(-) RNAs were synthesized in vitro by run off transcription with T7 RNA polymerase and transfected into NDV-infected chick embryo fibrolast DF1 cells (a gift of D.N. Foster, University of Minnesota). NDV(-) RNA was amplified, expressed, and packaged into RNAse resistant particles that could be used to infect fresh cells (Fig. 5a and 5b).

A heterologous paramyxovirus, bovine parainfluenze virus 3, failed to rescue NDV-CAT RNA. Passage of NDV minigenome particles were specifically neutralized by NDV antiserum. This procedures provides a sensitive system for characterizing the cis-acting nucleotide sequences required for transcription, replication, and packaging of NDV genomic RNA. The results in Fig. 5 showed that the 3' to 5' ends of NDV genomic RNA contain all the cis-acting sequences required for transcription and replication of NDV RNA. In other words, the leader and trailer sequences were functional.

The present inventor also discovered, using this system, that (i) MDBK, HEp 2, HeLa, 293, and vero cells also rescued NDV minigenome, (ii) higher multiplicity of infection (>10 PFU) of superinfecting NDV had deleterious effect on rescue of NDV minigenome, (iii) time of superinfection with NDV (0-2 hours before transfection) had no effect on rescue of NDV minigenome, and (iv) removal of 3' terminal U residue had no deleterious effect on minigenome rescue.

D. Evaluation of the Rule of Six in NDV

RNA replication by certain paramyxoviruses is efficient only if the nucleotide length of the genome is a multiple of six (the "rule of six"). This rule holds for Sendai virus, measles virus, and parainfluenza virus but does not hold for rabies virus, vesicular stomatitis virus, and respiratory syncytial virus. Interestingly, the genome of NDV strain Beaudette C is 15,186 nucleotides which is a multiple of six. To determine whether NDV follows the rule of six, three additional NDV minigenomes of 976, 980, and 981 nucleotides were constructed by changing the number of nucleotides in the NP noncoding region of the original NDV minigenome. These

minigenomes represented multiples of 2 through 10. It was observed that the genome length of NDV must be a multiple of six for efficient transcription, replication, and packaging. This information is useful in the construction of full length NDV and cDNA.

E. Identification of trans-acting proteins required for transcription and replication of NDV RNA

NDV-CAT(-) cDNA was constructed to encode a 978 nucleotide negative-sense NDV-CAT RNA or minigenome, containing the CAT gene flanked by gene-start and gene-end sequences and by the genome termini. A schematic of NDV-CAT(-) is shown in Fig. 6. A NDV(-) minigenome was modified to contain an 84-nucleotide hepatitis delta virus antigenome ribozyme sequence at the leader end to execute self-cleavage to generate nearly exact 3' end. A plasmid containing the HDV ribozyme sequence followed by T7 transcription terminator was used to construct NDV-CAT(-) by PCR.

NDV-CAT(-) cDNA was transfected into DF1 cells infected with a vaccinia virus recombinant expressing T7 RNA polymerase, together with plasmids encoding NDV NP, P, and L proteins each under the control of a T7 promoter. Assay of cell lysate 48 hours after transfection showed expression of CAT (Fig. 7), indicating transcription and replication of NDV minigenome. Omission of any of the three viral proteins abrogated transcription and replication, thereby defining the N, P, L proteins are the minimal *trans*-acting proteins required for transcription and replication of NDV RNA. These results show that infectious NDV can be produced from cloned cDNA.

F. Construction of a full-length NDV cDNA clone.

A cDNA clone encoding the entire 15,186-nt antigenome of NDV strain Beaudette C was constructed from eight cDNA segments that were synthesized by RT-PCR from virion derived genomic RNA (Fig. 8). Each cDNA segment was completely sequenced before assembly into the full-length cDNA clone. The leader end was constructed to join the promoter for T7 RNA polymerase. To generate a nearly exact 3' end, the trailer end was constructed to join hepatitis delta virus antigenome ribozyme sequence followed by tandem terminators of T7 transcription.

Two restriction site markers were introduced into the antigenomic cDNA by incorporating the changes into the oligonucleotide primers used in RT-PCR. This was done to identify recombinant virus. An *Mlu* I site was created in the F-HN intergenic region and the other unique *Age* I site was created in the HN-L intergenic region.

Within the scope of the present invention is a method of producing NDV produced from cDNA, e.g. full length cDNA (see Fig. 9 for a schematic representation of one of the embodiments of the method). The method comprises the following steps:

(1). providing a plasmid comprising a promoter and a cDNA encoding the antigenome of NDV;

(2). providing a plasmid comprising the gene for NDV NP protein under the control of a promoter;

(3). providing a plasmid comprising the gene for NDV P protein under the control of a promoter;

(4). providing a plasmid comprising the gene for NDV L protein under the control of a promoter;

(5). transfecting cells in a medium with a mixture of the plasmids of steps (1)-(4); and thereafter

(6). isolating NDV from the cells or the medium.

In a preferred embodiment of the method, a leader end of the cDNA in step (1) is joined with a promoter for T7 RNA polymerase, the promoter in steps (2)-(4) are promoters for T7 RNA polymerase, and the cells in step 5 are also transfected with vaccinia virus that expresses T7 RNA polymerase. In a more preferred embodiment of the method, a leader end of the cDNA in step (1) is joined with a promoter for T7 RNA polymerase and a trailer end of the cDNA in step (1) is joined with hepatitis delta virus antigenome ribozyme sequence followed by tandem terminators of T7 transcription, the promoter in steps (2)-(4) are promoters for T7 RNA polymerase, and the cells in step 5 are also transfected with vaccinia virus, e.g. strain MVA, that expresses T7 RNA polymerase. In the method of production of NDV from cDNA, the cDNA in step (1) can encode for the complete sequence of the antigenome of NDV or a sequence of the antigenome of NDV with some of the

nucleotides or genes missing. In another preferred embodiment of the method, the cDNA can contain at least one, e.g. 2 or 3, restriction sites as markers. The cells in step (5) can be animal cells, such as mammalian cells or avian cells, or plant cells, but avian cells, e.g. HEp-2 cells, are preferred because these cells are permissive to NDV but resistant to cytopathic effects of vaccinia virus strain MVA. Cell lines expressing T7 RNA polymerase can be used.

F. Recovery and characterization of infectious NDV from cDNA

(i) Recovery of infectious NDV ftom cDNA.

Confluent monolayers of HEp-2 cells in six-well dishes were infected with I PFU per cell of recombinant vaccinia virus strain MVA that expresses T7 RNA polymerase (MVA-TI) (a gift of Dr. B. Moss, NIH). A mixture of three plasmids containing the NDV NP, P and L each under the control of the T7 promoter and a fourth plasmid encoding the full-length NDV antigenome was transfected with LipofectACE (Life Technologies). Twelve hours later the medium was replaced with medium containing 40μ g of cytosine arabinoside per ml to inhibit the replication of vaccinia virus. After 4 days the medium supernatant was centrifuged for 10 min. at 14,000 xg to remove vaccinia virus and passaged onto fresh HEp-2 cells in presence of cytosine arabinoside io further inhibit growth of any residual vaccinia virus. The final supernatant after a second passage in HEp-2 cells was plaque assayed on chick embryo fibroblast cell line DF I under 1% agarose. Several NDV plaques were picked and amplified in DF I cells.

(ii) Characterization of recovered NDV.

The recovered virus was identified as NDV by plaque assay and positive immunostaining using HN-specific monoclonal antibodies. A,comparison of size and morphology of plaques between recovered NDV and laboratory Beaudette C strain did not show any difference (Fig. 10). To verify that the two restriction site markers inserted into the full-length CDNA were present in the recovered NDV, the F-HN and HN-L intergenic regions were amplified by RT-PCR. Restriction enzyme digestion (Fig. 11) showed that the PCR products representing the recombinant virus contained the expected restriction site markers while those representing the laboratory strain did not. In Fig. 11, lane 1 represents *Mlu* I digested RT/PCR product of laboratory

Beaudette C strain across F-HN intergenic region; lane 2 represents *Mlu* I digested RT/PCR product of recombinant Beaudette C strain across F-HN intergenic region; lane 3 represents *Age* I digested RT/PCR product of laboratory Beaudette C strain across HN-L intergenic region; and lane 4 represents *Age* I digested RT/PCR product of recombinant Beaudette C strain across HN-L intergenic region. Control experiments confirmed that the PCR product was dependent on reverse transcription. Nucleotide sequence analysis of cloned PCR products confirmed the sequences spanning the restriction site markers. The growth characteristics of recombinant NDV and wild-type NDV strain Beaudette C were compared in DF I cells. There was no appreciable difference in the growth kinetics between the two viruses (Fig. 16 and 17). The recombinant NDV strain and the wild-type NDV strain Beaudette C were also studied with NDV antiserum or monoclonal antibodies and the results are shown in Table 1 below.

Table 1

HI Titers of Antisera and mAbs

	Titer[a]			
Strain	NDV Serum	mAb AVS	mAb 15C4	mAb 10D11
pNDV	4096	8	4096	256
rNDV	8192	32	8192	512

[a]Expressed as reciprocal of the highest dilution that caused inhibition of haemagglutination. Results for control serum were negative.

The results in Table 1 show that the recombinant NDV, rNDV, and the wild type NDV, pNDV, were immunologically similar.

There was also no difference in the mean death time (MDT) for chicken embryos between the two viruses as shown in Table 2 below.

Table 2

Strain	Mean Death Time in Eggs	Pathotype
pNDV	60 hours	Mesogenic
rNDV	62 hours	Mesogenic
La Sota	106 hours	Lentogenic

G. Construction of NDV with mutations in the fusion protein cleavage site.

The fusion protein is thought to be the major determinant of the virulence of NDV strains. Cleavability of the precursor fusion protein Fo to F, and F2 in a range of cell types correlates well with the pathogenicity of viral strains in chickens. The differences in cleavability of the Fo protein are thought to be due to sequence differences at the cleavage site. Avirulent strains have few basic amino acid residues (x-Arg/Lys-x-x-Arg) at the F_0 protein cleavage site, whereas virulent strains have multibasic residues (Arg-Arg-x-Arg/Lys-Arg) at the Fo protein cleavage site. Furthermore, in some avirulent strains a leucine residue is present at the N terminus of the F_1 cleavage fragment in place of a phenylalanine residue at this position in virulent strains. The present inventor examined the role of the sequences at the F protein cleavage site in NDV pathogenesis.

Cleavage site mutants were generated by sequential PCR mutagenesis. cDNA fragments containing the mutations were then assembled into the full-length cDNA clone. Two unique restriction enzyme sites, Apa I (position 4550 in the complete 15,186-nt antigenome sequence) and Not I (position 4953), were used to replace the wild-type fragment containing mutations at the cleavage site. A total of seven NDV mutants representing all possible structures of the cleavage site between velogenic and lentogenic strains were recovered (Fig. 12). Mutant I whose cleavage site is same as lentogenic strains was avirulent to chick embryos by MDT. Where as mutants 2 and 3 were of intermediate virulence to chick embryos by MDT.

H. Recovery of NDV expressing an additional, foreign gene.

The genome of NDV can be used to express an additional gene. For instance, the following experiment showed that the chloramphenicol acetyltransferase (CAT) gene is an example of the additional foreign gene. CAT gene was inserted into the HN-L intergenic region. The sequence in the HN-L intergenic region was modified to contain a unique Sna B I site downstream of the Age I site. The open reading frame (ORF) encoding the CAT protein was engineered to be flanked by the NDV GS and GE signals. This transcription cassette was inserted into the HN-L intergenic region of NDV antigenomic cDNA (Fig. 13). In this construct, care was

taken over the genome length requirement called the "rule of six". NDV has a preference but not an absolute requirement for a genome of 6 n length. A recombinant NDV containing the CAT gene was recovered using the strategy described before. RT-PCR of the genomic RNA isolated from the recovered virus showed the presence of the inserted CAT gene. The recovered virus expressed abundant levels of CAT enzyme (Fig. 14, lane 1 shows data from laboratory Beaudette C strain; lane 2 shows data from recombinant Beaudette C strain containing the CAT gene). Analysis of mRNAs by Northern blot hybridization showed that the CAT gene was expressed as an additional, separate, poly(A) mRNA. CAT expression was stable for at least 8 passages, indicating that the activity of the CAT protein encoded by NDV remained unimpaired by mutation. There was no appreciable difference either in plaque phenotype or in growth kinetics between the recovered virus and wild-type laboratory strain. This study showed that NDV can tolerate an increase of genome length of at least 690 nucleotides.

I. Generation of recombinant lentogenic NDV strain LaSota from cDNA.

In order for the recombinant NDV to be used as a vaccine vector, the vector itself should not produce any disease. The recombinant NDV strain Beaudette C produced by the present invention is a mesogenic strain. Within the scope of the present invention is the generation of recombinant lentogenic NDV for vector purposes. The present inventor rescued NDV strain LaSota because the complete nucleotide sequence of this strain is available. The NDV strain LaSota was received from Dr. Henry Stone (East Carolina University). This sample was only one egg passage away from the original "NJ LaSota 1953" isolate in the University of Wisconsin collection. A cDNA clone encoding the entire 15,186-nt antigenome of NDV strain LaSota was constructed from seven different cDNA fragments. Each cDNA fragment was completely sequenced before assembly. Comparison of the nucleotide sequence of the LaSota strain used here with the published sequence of NDV strain LaSota showed differences in 27 nucleotides distributed throughout the entire genome. Another difference found was that the L gene of the LaSota strain used here contained a double frameshift resulting in a 28 amino acid difference

located in block V. This double frameshift had been found in NDV strain Beaudette C in the prior art and recently had also been reported in NDV strain LaSota in the prior art. Thus, it indicates that the original LaSota strain has undergone genetic changes probably due to point mutations. To verify the recovery of NDV strain LaSota from cDNA, the nucleotide sequences were altered to create a Mlu I site in the F-HN intergenic region and Sna B I site at HN-L intergenic region. These two sites are not present either in laboratory LaSota strain or in NDV Beaudette C strain. Recovery of recombinant NDV strain LaSota was carried out using the method described before except that the supernatant after transfection was inoculated into the allantoic cavity of 10-day-old embryonated chicken eggs to amplify the recovered recombinant virus. RT-PCR of genomic RNA of recombinant NDV strain LaSota across these sites confirmed that the recovered virus was NDV strain LaSota (Fig. 15, in which lane 1 represents PCR of F-HN intergenic region of recombinant LaSota strain without RT; lane 2 represents RT/PCR of F-HN intergenic region of recombinant LaSota strain; lane 3 represents *Mlu* I digestion of lane 2 product; lane 4 represents PCR of F-HN intergenic region of laboratory LaSota strain without RT; lane 5 represents RT/PCR of F-HN intergenic region of laboratory LaSota strain; and lane 6 represents *Mlu* I digestion of lane 5 product).

In one of the embodiments of the present invention, infectious NDV was produced by the intracellular coexpression of four plasmid-borne cDNAs. One cDNA encoded a complete positive-sense version NDV genome, and each of the other three encoded a separate NDV protein, namely the nucleocapsid protein (NP), the phospoprotein (P) and the large protein (L). Each cDNA in the plasmid was under the control of a T7 RNA promoter. The full-length cDNA of NDV Strain Beaudette C was assembled by ligation of eight different RT-PCR fragments. Monolayer cultures of HEp-2 cells were infected with vaccinia virus Strain MVA expressing T7 RNA polymerase and transfected with the four different plasmids. On day 3 clarified medium supernatants were passaged onto fresh chick embryo fibroblast cells and overlaid with agarose for plaque purification. Individual NDV plaques were picked passaged in fresh chick embryo fibroblast cells. Our results showed NDV was produced when all four plasmids were used in transfection. NDV

was not produced if any of the four plasmid was omitted. Recovery of NDV from cDNA was verified by (i) the presence of two genetic tags generating restriction sites in cDNA derived from the genome and (ii) and direct sequencing of the genomic RNA of the recovered virus. These results show that recombinant NDV can be recovered from cDNA and the genome of NDV can be manipulated at the cDNA level.

In the present invention, the genome of NDV can be directly manipulated. With the manipulation of the genome of NDV, one can (i) introduce multiple attenuation mutations to create stable vaccine virus, (ii) create new types of attenuation mutations, which might include deletion of the viral genome, (iii) change the cleavage site of F and HN proteins to create completely apathogenic vaccine strains, (iv) change the gene order of the virus so the immunogenic proteins are expressed in large amounts, (v) modify vaccine virus to accommodate antigenic drift in circulating virus, (vi) the length of the intergenic sequences can be changed to create attenuating viruses, (vii) create NDV that does not express V protein, and (viii) insert foreign sequences into the NDV genome for coexpression. For example, the gene for protective antigen of another avian pathogen or the genes for avian cytokines can be inserted into the NDV genome for coexpression.

In the present invention, production of infectious NDV from cloned cDNA will be useful to (i) provide stable vaccine seed, (ii) introduce attenuation mutations into the genome of NDV to create stable, completely apathogenic vaccine virus strains, (iii) engineer NDV carrying foreign genes. For example, the gene for protective antigen of another avian pathogen or the genes for cytokines can be inserted into the NDV genome for coexpression.

Also within the scope of the present invention are the products listed below.

(i) A genetically engineered NDV vaccine that is better than currently available NDV vaccines.

(ii) Multivalent genetically engineered NDV vaccines carrying immunogens for influenza virus, infectious bursal disease virus, rotavirus, infectious bronchitis virus, infectious laryngotracheitis

virus, chicken anemia virus, Marek's disease virus, avian Leukosis virus and avian adenovirus.

(iii) A genetically engineered NDV carrying avian cytokine genes.

Within the scope of the present invention are an isolated nucleic acid encoding the entire genome of NDV Beaudette C strain ("isolated" herein means a substantially purified nucleic acid or, optionally, a substantially purified nucleic acid without the proteins of NDV Beaudette C strain), the 5' trailer nucleotide sequence of NDV Beaudette C strain, an isolated nucleic acid encoding the NP protein of NDV Beaudette C strain ("isolated" herein means a substantially purified nucleic acid or, optionally, a substantially purified nucleic acid without the proteins of NDV Beaudette C strain), the 5' trailer nucleotide sequence of NDV Beaudette B1 strain, the leading nucleotide sequence of NDV Beaudette B1 strain. Also within the scope of the present invention are vaccines for NDV. These vaccines can be administered orally, intranasally, intraocularly or parenterally, e.g. by intramuscular or subcutaneous injection, to an avian host in need of vaccination against NDV at a dose of $1x10^4$ EID_{50} to $1x10^9$ EID_{50} per bird, or preferably $1x10^5$ EID_{50} to $1x10^8$ EID_{50} per bird, or more preferably $1x10^6$ EID_{50} to $1x10^7$ EID_{50} per bird (EID means "embryo infective dose"). However, the route of administration and dose can be adjusted, by one skilled in the art, based on the condition of the avian host and the virulence of the NDV that the vaccination is aimed at preventing.

An aspect of the present invention is a synthetic cDNA which encodes an infectious Newcastle Disease Virus (NDV), which is optionally attenuated.

Another aspect of the present invention is a vector containing a synthetic cDNA which encodes an infectious NDV, optionally linked to an operable promoter.

Another aspect of the present invention is a host cell containing a synthetic cDNA which encodes an infectious NDV.

Within the scope of the present invention is a method of producing infectious NDV comprising inserting a synthetic cDNA which encodes an infectious NDV into a host cell, wherein the cDNA is operably-linked to a promoter; and expressing the cDNA in the host cell to produce the infectious NDV.

An embodiment of the present invention is an infectious NDV, produced by the following method: inserting a synthetic cDNA which encodes infectious NDV into a host cell, wherein the cDNA is operably-linked to a promoter; and expressing the cDNA in the host cell to produce the infectious NDV.

Another embodiment of the present invention is a vaccine comprising an infectious NDV which has been attenuated by introducing at least one RNA point mutation thereon, wherein the infectious NDV has been produced by the following method:

inserting a synthetic cDNA which encodes an infectious NDV into a host cell, wherein the cDNA is operably-linked to a promoter; and expressing the cDNA in the host cell to produce the infectious NDV.

Within the scope of the present invention is a vaccine for Newcastle disease comprising a Newcastle disease virus, wherein the Newcastle disease virus has at least two of the features selected from the group consisting of (1) a F_0 protein cleavage site having at least two less basic amino acid residues than a F_0 protein cleavage site of Newcastle disease virus wild type strain Beaudette C; (2) an amino acid having a non-aromatic side chain at the N terminus of the F_1 cleavage fragment, wherein the amino acid having a non-aromatic side chain is glycine, alanine, valine, leucine or isoleucine, preferably leucine; and (3) an open reading frame of a HN glycoprotein being longer than an open reading frame of a HN glycoprotein of Newcastle disease virus wild type strain Beaudette C. Preferably, in the vaccine, the Newcastle disease virus has a F_0 protein cleavage site having serine or glycine independently replacing at least two basic amino acid residues of the F_0 protein cleavage site of Newcastle disease virus wild type strain Beaudette C. Also preferably, in the vaccine, the F_0 protein cleavage site has at least two less basic amino acid residues than a F_0 protein cleavage site of Newcastle disease virus wild type strain Beaudette C, wherein said at least two basic amino acid residues are arginine or lysine. In the vaccine, more preferably, the Newcastle disease virus has at least one of the following features: (i) a codon, TCC, for serine in place of the codon for an arginine residue at the -2 position of the F_0 protein cleavage site of Newcastle disease virus wild type strain Beaudette C, and (ii) a codon, TCC, for

serine in place of the codon for an arginine residue at the -5 position of the F_0 protein cleavage site of Newcastle disease virus wild type strain Beaudette C. In the vaccine, more preferably, the Newcastle disease virus has at least one of the following two features: (i) a codon, TCC, for serine in place of the codon for an arginine residue at the -2 position of the F_0 protein cleavage site of Newcastle disease virus wild type strain Beaudette C, and (ii) a codon, TCC, for serine in place of the codon for an arginine residue at the -5 position of the F_0 protein cleavage site of Newcastle disease virus wild type strain Beaudette C; and has the amino acid, i.e. leucine, having a non-aromatic side chain at the N terminus of the F_1 cleavage fragment. More preferably, the codon for the leucine in the cDNA that makes the virus in the vaccine is CTC. Optionally, the Newcastle disease virus in the vaccine carries at least one gene encoding an avian cytokine, e.g. an interleukin such as IL-2 and IL-4.

Also within the scope of the present invention is an isolated nucleic acid comprising a sequence of 15,186 nucleotides as described in Figure 2.

Another embodiment of the present invention is an isolated nucleic acid of up to 200, 150, 100 or 75 nucleotides in length, comprising a sequence of 55 nucleotides of the leader region described in Figure 2. Another embodiment of the present invention is an isolated protein encoded by the isolated nucleic acid.

Another embodiment of the present invention is an isolated nucleic acid consisting essentially of or consisting of the sequence of 55 nucleotides of the leader region described in Figure 2. Another embodiment of the present invention is an isolated protein encoded by the isolated nucleic acid.

Another embodiment of the present invention is an isolated nucleic acid of up to 350, 250 or 150 nucleotides in length, comprising a sequence of 113 nucleotides of the trailer region described in Figure 2. Another embodiment of the present invention is an isolated protein encoded by the isolated nucleic acid.

Another embodiment of the present invention is an isolated nucleic acid consisting essentially of or consisting of the sequence of 113 nucleotides of the leader region described in Figure 2. Another embodiment of the present invention is an isolated protein encoded by the isolated nucleic acid.

Another embodiment of the present invention is an isolated nucleic acid of up to 2500 or 2000 nucleotides in length comprising the nucleotide sequence of the NP region described in Figure 2 (the nucleotide sequence of the NP region is available from the GenBank database with the accession number AF064091). Another embodiment of the present invention is an isolated protein encoded by the isolated nucleic acid.

Another embodiment is an isolated nucleic acid consisting essentially of or consisting of the nucleotide sequence of the NP region is available from the GenBank database with the accession number AF064091. Another embodiment of the present invention is an isolated protein encoded by the isolated nucleic acid.

Within the scope of the present invention is a method of producing infectious Newcastle disease virus, comprising the following steps:

inserting a cDNA encoding the infectious Newcastle disease virus into a host cell, wherein the cDNA is operably-linked to a promoter; and

expressing the cDNA in the host cell to product the infectious Newcastle disease virus.

The method preferably further comprises purifying the infectious Newcastle disease virus.

Within the scope of the present invention are vectors containing the cDNA that can be prepared by the methods or information disclosed in this patent application, optionally linked to an operable promoter.

Another aspect of the present invention is a method of preventing or treating Newcastle disease in an avian subject by administering a vaccine against Newcastle disease virus.

The present invention shows that infectious NDV can be recovered from cloned cDNA. Both virulent and avirulent strains of NDV (as demonstrated by Beaudette C and LaSota) can be recovered from cDNAs. The present invention also shows that a foreign gene, chloramphenical acetyltransferase (CAT), can be introduced into the genome of NDV and the CAT protein was expressed in infected cells. Thus, recombinant NDV can be used to express proteins of other avian pathogens. Therefore, the NDV can be used as a vaccine vector. The present

invention also presents a method to recover NDV with mutations in the F protein cleavage site. This result shows that the cleavage site of currently used live attenuated vaccines, e.g. LaSota, can mutate to revert back to virulence relatively easily.

REFERENCES

1. Alexander, D.J. (1991). Newcastle Disease and other paramyxoviruses. In: Diseases of poultry, glh ed. Calnek B.W. edited. Iowa State University Press, Ames, Iowa. pp 496-519.

2. Murphy, F.A., Fauquet, C.M., Bishop, D.H.L., Ghabrial, S.A., Jarvis, A.W., Martelli, G.P.,, Mayo, M.A., and Summers, M.D. (1995). Virus Taxonomy. Sixth Report of the

International Conunittee on Taxonomy of Viruses. Vienna & New York; Springer-Verlag.

3. Krishnamurthy, S. and Samal, S.K. (1997). Nucleotide sequences of the Trailer, Nucleocaspid protein gene and Intergenic regions of Newcastle Disease Virus strain Beaudette C and: Completion of the entire genome sequence. J. Gen. Virol. 79, 2419- 2424.

4. Peeples, M.E. (1988). Newcastle disease virus replication. In: Newcastle Disease, Alexander, D.J. edited. Kluwer Academic Published. pp 45-78.

5. Steward, M., Vipond, B., Miller, N.S., and Emmerson P.T. (1993). RNA editing in Newcastle disease virus. J. Gen Virol. 74, 2539-2547.

6. Homma, M. and Ohucei, M. (1973). Trypsin acyion on the growth of Sendai virus in tissue culture cells. IV. Structural difference of Sendai viruses grown in eggs and tissue culture cells. J. Virol. 12, 1457-1465.

7. Meulemans, G., Gonze, M., Carlier, M.C., Petit, A., Bumy, A., and Long, L. (1986). Protective effects of HN and F protein glycoprotein-specific monoclonal antibodies on experimental Newcastle disease. Avian Panthol. 15, 761-768.

8. Morgan, R.W., Gelb, J., Schreurs, L.S., Lutticken, D., Rosenberger, J.K. and Sondermeijer, P.J. (1992). Protection of chickens from Newcastle and Marek's diseases with a

recombinant herpes virus of turkeys vaccine expressing the Newcastle disease virus fusion protein. Avian Dis. 36, 858-870.

9. Steward, M., Samson, A.C.R., Erington, W. and Emerson, P.T. (1995). The Newcastle disease virus V protein binds zinc. Arch Virol. 140, 1321-1328.

10. Lamb, R.A. and Kolakofsky, D. (1996). Paramyxoviridae: the virusps and their replication. In Fields Virology; 3d ed. Fields, B.N., Knipe, D.M. and Howley, P.M. edited. Philadelphia, Lippincott-Raven.

What is claimed is:

1. A vaccine for Newcastle disease comprising a Newcastle disease virus Z, wherein the Newcastle disease virus Z has at least two of the features selected from the group consisting of (1) a F_0 protein cleavage site having at least two less basic amino acid residues than a F_0 protein cleavage site of Newcastle disease virus wild type strain Beaudette C; (2) an amino acid having a non-aromatic side chain at the N terminus of the F_1 cleavage fragment, wherein the amino acid having a non-aromatic side chain is glycine, alanine, valine, leucine or isoleucine; and (3) an open reading frame of a HN glycoprotein being longer than an open reading frame of a HN glycoprotein of Newcastle disease virus wild type strain Beaudette C.

2. The vaccine of claim 1, wherein in (1) the Newcastle disease virus Z has the F_0 protein cleavage site having serine or glycine independently replacing at least two basic amino acid residues of the F_0 protein cleavage site of Newcastle disease virus wild type strain Beaudette C.

3. The vaccine of claim 2, wherein in (1) said at least two basic amino acid residues of the F_0 protein cleavage site of Newcastle disease virus wild type strain Beaudette C replaced by serine or glycine are arginine or lysine.

4. The vaccine of claim 3, wherein in (1) the Newcastle disease virus Z has at least one of the following two features: (i) a codon, TCC, for serine in place of the codon for an arginine residue at the -2 position of the F_0 protein cleavage site of Newcastle disease virus wild type strain Beaudette C, and (ii) a codon, TCC, for serine in place of the codon for an arginine residue at the -5 position of the F_0 protein cleavage site of Newcastle disease virus wild type strain Beaudette C.

5. The vaccine of claim 1, wherein in (2) the amino acid having a non-aromatic side chain is leucine.

6. The vaccine of claim 4, wherein the Newcastle disease virus Z has at least one of the following two features: (i) a codon, TCC, for serine in place of the codon for an arginine residue at the -2 position of the F_0 protein cleavage site of Newcastle disease virus wild type strain Beaudette C, and (ii) a codon, TCC, for

cleavage site of Newcastle disease virus wild type strain Beaudette C; and has an amino acid having a non-aromatic side chain at the N terminus of the F_1 cleavage fragment, wherein the amino acid having a non-aromatic side chain is leucine.

7. The vaccine of claim 6, wherein the codon for leucine is CTC.

8. An isolated nucleic acid comprising a sequence of 15,186 nucleotides as described in Figure 2.

9. An isolated nucleic acid of up to 200 nucleotides in length, comprising a sequence of 55 nucleotides of the leader region described in Figure 2.

10. An isolated nucleic acid of up to 350 nucleotides in length, comprising a sequence of 113 nucleotides of the trailer region described in Figure 2.

11. An isolated nucleic acid of up to 2500 nucleotides in length, comprising the nucleotide sequence of the NP region described in Figure 2, wherein the nucleotide sequence of the NP region is available from the GenBank database with the accession number AF064091.

12. The isolated nucleic acid of claim 11 consisting of the nucleotide sequence of the NP region.

13. A method of producing a Newcastle disease virus, said method comprising the following steps:

(1). providing a plasmid comprising a promoter and a cDNA encoding the antigenome of Newcastle disease virus;

(2). providing a plasmid comprising the gene for Newcastle disease virus NP protein under the control of a promoter;

(3). providing a plasmid comprising the gene for Newcastle disease virus P protein under the control of a promoter;

(4). providing a plasmid comprising the gene for Newcastle disease virus L protein under the control of a promoter;

(5). transfecting cells in a medium with a mixture of the plasmids of steps (1)-(4); and thereafter

(6). isolating the Newcastle disease virus from the cells or the medium.

14. The method of claim 13, wherein a leader end of the cDNA in step (1) is joined with a promoter for T7 RNA polymerase, the promoter in steps (2)-(4) are

promoters for T7 RNA polymerase, and the cells in step 5 are also transfected with vaccinia virus that expresses T7 RNA polymerase.

15. The method of claim 13, wherein a leader end of the cDNA in step (1) is joined with a promoter for T7 RNA polymerase and a trailer end of the cDNA in step (1) is joined with hepatitis delta virus antigenome ribozyme sequence followed by tandem terminators of T7 transcription, the promoter in steps (2)-(4) are promoters for T7 RNA polymerase, and the cells in step 5 are also transfected with vaccinia virus that expresses T7 RNA polymerase.

16. The method of claim 13, wherein the cDNA contains at least one, e.g. 2 or 3, restriction sites as markers.

17. The method of claim 13, wherein the cells in step (5) are avian cells.

18. The method of claim 17, wherein the avian cells are HEp-2 cells.

19. The vaccine of claim 1, wherein in (1), the F_0 protein cleavage site has at least two less basic amino acid residues than a F_0 protein cleavage site of Newcastle disease virus wild type strain Beaudette C, wherein said at least two basic amino acid residues are arginine or lysine.

20. An isolated protein encoded by the nucleic acid of claim 11.

21. A synthetic cDNA which encodes an infectious Newcastle disease virus.

22. A vector containing the cDNA of claim 21.

23. A host cell containing the cDNA of claim 21.

24. A method of producting infectious Newcastle disease virus, comprising the following steps:

inserting a cDNA of claim 21 into a host cell, wherein the cDNA is operably-linked to a promoter; and

expressing the cDNA in the host cell to product the infectious Newcastle disease virus.

25. The method of claim 24, further comprising purifying the infectious Newcastle disease virus.

27. The vaccine of claim 26, wherein said cytokine is an interleukin.